Fumarate Hydratase Immunostain, Technical Component Only
Use
Identifying fumarate hydratase-deficient neoplasms and supporting the diagnosis of an atypical smooth muscle tumor over leiomyosarcoma. This test can play a crucial role in diagnosing hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome, which is linked to fumarate hydratase deficiency due to germline alterations in the FH gene. Such identification helps in determining appropriate clinical management and surveillance strategies for patients suspected of having these conditions.
Special Instructions
Not provided.
Limitations
The test is affected by the age of cut paraffin sections, as immunoreactivity can diminish over time and is dependent on antigen stability. Best practices suggest that paraffin sections should be cut within 6 weeks. Environmental factors may affect the charge of glass slides, influencing slide staining results. Optimal storage limits exposure to humidity, heat, and plastics to preserve the integrity of the slides.
FDA ApprovedNew York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Fumarate Hydratase
Protein
LOINC Codes
- Order only;no result
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Immunostain Technical Only Envelope
Collection Instructions
Attach the green "Attention Pathology" address label (T498) and the pink Immunostain Technical Only label to the transport container.
Causes for Rejection
Wet/frozen tissue, Cytology smears, Nonformalin fixed tissue, Nonparaffin embedded tissue, Noncharged slides, ProbeOn slides, Snowcoat slides